OncoTherapy Science, BioWa to Collaborate in Antibody Drug Development.Tokyo, Japan, Oct 25, 2005 - (JCNN JCNN Japan Corporate News Network ) - OncoTherapy Science and BioWa jointly announced on October 24 that the two companies have agreed to collaborate in research on cancer-focused monoclonal antibodies (MAbs). Targeting cancer-specific membrane protein owned by OncoTherapy, the two companies will create an antibody with improved ADCC ADCC antibody-dependent cell-mediated cytotoxicity. ADCC antibody-dependent cell-mediated cytotoxicity. (antibody-dependent cellular cytotoxicity) activity using BioWa's proprietary antibody technology POTELLIGENT. The ADCC activity is an anti-tumor mechanisms. Further, the partners will proceed with the development of antibody drugs with higher effectiveness and lesser side effects Side effects Effects of a proposed project on other parts of the firm. . BioWa's POTELLIGENT technology can increase the level of the ADCC activity about 100-fold. Currently, BioWa licenses POTELLIGENT to Medarex and Biogen Idec. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion